Last reviewed · How we verify

sofosbubir/velpatasvir/voxilaprevir

Partners in Health · FDA-approved active Small molecule

This combination inhibits three different hepatitis C virus enzymes (NS5B polymerase, NS5A protein, and NS3/4A protease) to block viral replication.

This combination inhibits three different hepatitis C virus enzymes (NS5B polymerase, NS5A protein, and NS3/4A protease) to block viral replication. Used for Chronic hepatitis C virus infection (genotypes 1-6), including treatment-experienced patients with compensated cirrhosis.

At a glance

Generic namesofosbubir/velpatasvir/voxilaprevir
Also known asVosevi
SponsorPartners in Health
Drug classDirect-acting antiviral (DAA) combination
TargetHCV NS5B polymerase, NS5A protein, NS3/4A protease
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

Sofosbuvir is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase. Velpatasvir inhibits the NS5A protein, which is essential for viral replication and assembly. Voxilaprevir inhibits the NS3/4A serine protease. Together, these three agents target complementary steps in the HCV life cycle, providing a pangenotypic direct-acting antiviral regimen.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: